Literature DB >> 7041594

Role of sympathetic nervous system activity in the blood pressure response to long-term captopril therapy in severely hypertensive patients.

M H Weinberger.   

Abstract

Twenty severely hypertensive subjects who did not achieve blood pressure control with combination therapy with a vasodilator, a beta-adrenergic blocking agent and a diuretic received the angiotensin-converting enzyme inhibitor captopril. Marked decreases in blood pressure were observed immediately. Achievement of sustained reductions in blood pressure into the normal range for up to 3 years of follow-up required the addition of a diuretic in all patients and of a beta-adrenergic blocking agent in half. As expected, significant increases in plasma renin activity and decreases in plasma aldosterone were seen initially and sustained throughout the study. Plasma and urinary norepinephrine levels, which were markedly increased before captopril treatment, decreased significantly and remained low for the duration of study. These observations suggest a link between the renal pressor and sympathetic systems which may be involved in the pathophysiology of severe, treatment-resistant hypertension, and suggest that part of the antihypertensive action of captopril may be related to a decrease in sympathetic activity secondary to its interference with the generation of angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7041594     DOI: 10.1016/0002-9149(82)90383-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis.

Authors:  F R Ibarra; C Afione; D Garzon; M Barontini; J C Santos; E Arrizurieta
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Circulating and tissue angiotensin systems.

Authors:  D J Campbell
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

Review 3.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

4.  Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension.

Authors:  M H Weinberger
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

5.  Enalapril versus combined enalapril and nadolol treatment: effects on blood pressure, heart rate, humoral variables, and plasma potassium at rest and during exercise in hypertensive patients.

Authors:  P A Sullivan; B Daly; R O'Connor
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

6.  Elevated sympathetic nerve activity in patients with accelerated essential hypertension.

Authors:  T Matsukawa; T Mano; E Gotoh; M Ishii
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

7.  Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure.

Authors:  P Daly; J L Rouleau; D Cousineau; J H Burgess; K Chatterjee
Journal:  Br Heart J       Date:  1986-08

8.  Effect of alacepril on blood pressure and neurohumoral factors at rest and during dynamic exercise in patients with essential hypertension.

Authors:  T Kinugawa; H Kitamura; K Ogino; N Noguchi; T Matsumoto; I Hisatome; H Miyakoda; H Kotake; H Mashiba
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 9.  Angiotensin converting enzyme inhibitors in the treatment of hypertension: efficacy, metabolic effects and side effects.

Authors:  M H Weinberger
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.